Mechanism of factor VIIa-dependent coagulation in hemophilia blood

被引:167
作者
Butenas, S [1 ]
Brummel, KE [1 ]
Branda, RF [1 ]
Paradis, SG [1 ]
Mann, KG [1 ]
机构
[1] Univ Vermont, Dept Biochem, Burlington, VT 05405 USA
关键词
D O I
10.1182/blood.V99.3.923
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ability of factor VIIa to initiate thrombin generation and clot formation in blood from healthy donors, blood from patients with hemophilia A, and in anti-factor IX antibody-induced ("acquired") hemophilia B blood was investigated. In normal blood, both factor VIIa-tissue factor (TF) complex and factor VIIa alone initiated thrombin generation. The efficiency of factor VIIa was about 0.0001 that of the factor VIIa-TF complex. In congenital hemophilia A blood and "acquired" hemophilia B blood in vitro, addition of 10 to 50 nM factor VIIa (pharmacologic concentrations) corrected the clotting time at all TF concentrations tested (0-100 pM) but had little effect on thrombin generation. Fibrinopeptide release and insoluble clot formation were only marginally influenced by addition of factor VIIa. TF alone had a more pronounced effect on thrombin generation; an increase in TF from 0 to 100 pM increased the maximum thrombin level in "acquired" hemophilia B blood from 120 to 480 nM. Platelet activation was considerably enhanced by addition of factor VIIa to both hemophilia A blood and "acquired" hemophilia B blood. Thus, pharmacologic, concentrations of factor VIIa cannot restore normal thrombin generation in hemophilia A and hemophilia B blood in vitro. The efficacy of factor VIIa (10-50 nM) in hemophilia blood is dependent on TF. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:923 / 930
页数:8
相关论文
共 65 条
[51]   FACTOR-VII DEFICIENCY [J].
RAGNI, MV ;
LEWIS, JH ;
SPERO, JA ;
HASIBA, U .
AMERICAN JOURNAL OF HEMATOLOGY, 1981, 10 (01) :79-88
[52]   Blood clotting in minimally altered whole blood [J].
Rand, MD ;
Lock, JB ;
vantVeer, C ;
Gaffney, DP ;
Mann, KG .
BLOOD, 1996, 88 (09) :3432-3445
[53]   Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: advantages of administration by continuous infusion over bolus intermittent injections [J].
Scaraggi, FA ;
De Mitrio, V ;
Marino, R ;
Speciale, V ;
Di Bari, L ;
Petronelli, M ;
Schiraldi, O .
BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (01) :33-38
[54]   Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: Safety, monitoring, and cost effectiveness [J].
Schulman, S .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (04) :421-424
[55]  
SCHULMAN S, 1984, ACTA MED SCAND, V215, P249
[56]   HUMAN RECOMBINANT DNA-DERIVED ANTIHEMOPHILIC-FACTOR (FACTOR-VIII) IN THE TREATMENT OF HEMOPHILIA-A [J].
SCHWARTZ, RS ;
ABILDGAARD, CF ;
ALEDORT, LM ;
ARKIN, S ;
BLOOM, AL ;
BRACKMANN, HH ;
BRETTLER, DB ;
FUKUI, H ;
HILGARTNER, MW ;
INWOOD, MJ ;
KASPER, CK ;
KERNOFF, PBA ;
LEVINE, PH ;
LUSHER, JM ;
MANNUCCI, PM ;
SCHARRER, I ;
MACKENZIE, MA ;
PANCHAM, N ;
KUO, HS ;
ALLRED, RU .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (26) :1800-1805
[57]   Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors [J].
Shapiro, AD .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (04) :413-419
[58]  
Shapiro AD, 1998, THROMB HAEMOSTASIS, V80, P773
[59]   Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors [J].
Snyder, RO ;
Miao, CH ;
Patijn, GA ;
Spratt, SK ;
Danos, O ;
Nagy, D ;
Gown, AM ;
Winther, B ;
Meuse, L ;
Cohen, LK ;
Thompson, AR ;
Kay, MA .
NATURE GENETICS, 1997, 16 (03) :270-276
[60]   FACTOR-IX CONCENTRATES FOR CLINICAL USE [J].
THOMPSON, AR .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1993, 19 (01) :25-36